The New Center Aims to Develop and Offer High-Quality Products That Meet the Specific Requirements of the Chinese and Other Emerging Market Economies
SHANGHAI, CHINA--(Marketwired - Nov 17, 2015) - Fresenius Medical Care, the world's leading renal company, inaugurated the new China Design Center (CDC) located in Caohejing Hi-Tech Park in the Minhang District in Shanghai with an opening ceremony on 27 October 2015. The new state-of-the-art facility signals an important step towards consolidating the company's position as the global leader in dialysis products while servicing millions of renal patients in China and the AsiaPacific region.
"We are extremely excited about Fresenius Medical Care's future in China," said Dr. Alan Chan, Executive Vice President of Fresenius Medical Care, China. "We have been in this market for many years and the feedback from Chinese patients and clinicians tells us that they truly appreciate the quality that our brand represents."
As a part of the company's Global Research & Development (GRD) division, the new CDC will link with Procurement, local Global Manufacturing and Quality Organization (GMQ) facilities as well as Sales and Marketing teams to consolidate the company's international expertise with key Chinese academia and highly-trained local talent to develop a deeper insight into the needs of the growing patient base in the region and produce cost-effective products that meet the highest medical standards.
"We decided to open the China Design Center here because the well-qualified engineers in Shanghai, excellent suppliers and a rapidly developing healthcare system, make this the perfect place for us, " said Dr. Olaf Schermeier, CEO for Global R&D, Member of the Fresenius Medical Care Management Board. "Millions of patients across China and the Asia-Pacific region with kidney disease still have no access to proper treatment and the opening of the China Design Center is set to change this."
In his opening speech, Dr. Schermeier announced an investment of USD100 million over the next years toward the development of high-quality basic renal therapies at affordable costs. Fresenius Medical Care also plans to double the employee base of the Center within the next year.
"We are recruiting the best and the brightest specialists with different technical backgrounds to meet our high requirements and complement our international R&D teams," said Roberto Fusté, President and CEO of Fresenius Medical Care, Asia-Pacific Region. "With the opening of the China Design Center, we demonstrate our commitment to continuously improving therapy offerings. We are excited to take this important step of providing high quality and affordable renal solutions for patients in China and across the region."
The opening ceremony for the China Design Center included key members of Fresenius Medical Care, representatives of the Caohejing Hi-Tech Park as well as officers of the Minhang District Administration.
Participant Names and Titles in Attached Image (L-R):
Dr. Kirill Koulechov, General Manager - China Design Center
Prof. Xueqing Yu, Director of the committee, the Chinese Society of Nephrology
Dr. Olaf Schermeier, CEO, Global Research and Development, Member of the Management Board of Fresenius Medical Care
Roberto Fusté, President and CEO, Asia Pacific Region, Member of the Management Board of Fresenius Medical Care
Joern Beissert, Vice Consul, Consulate General of the Federal Republic of Germany in Shanghai
Shengyang Wang, Vice director in Minhang District, the standing committee of National people's congress
Yan Shen, Head of Caohejing Hi-Tech Park
ABOUT FRESENIUS MEDICAL CARE:
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which more than 2.6 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,402 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 290,250 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.
For more information visit the company's website at www.freseniusmedicalcare.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Ms. Eonjung Lim
Fresenius Medical Care
Email: Email Contact